Aeterna Zentaris gets DSMB green-lights to continue Phase III trial for zoptarelin doxorubicin to treat endometrial cancer

13 October 2015

Aeterna Zentaris (Nasdaq: AEZS) on Tuesday said Data and Safety Monitoring Board (DSMB) has recommended the late stage trial for zoptarelin doxorubicin to treat advanced, recurrent or metastatic endometrial cancer, continue as planned.

The DSMB's decision follows completion of its pre‑specified second interim analysis on efficacy and safety for the ZoptEC Phase III trial at about 192 events, the company said.

David Dodd, chief executive of Aeterna Zentaris, said: "This positive second recommendation from the DSMB is an important milestone since it supports our continuation of the ZoptEC Phase III trial in endometrial cancer until its completion. The DSMB recommendation was based upon a comprehensive review of the data on efficacy and safety. We believe that zoptarelin doxorubicin has the potential to become the first FDA approved medical therapy for advanced, recurrent endometrial cancer.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK